Start the conversation
I'm calling 2:40 p.m. on Nov. 7, 2018, the "Sessions bump."
That's the moment we learned that former U.S. Attorney General Jeff Sessions resigned.
Sessions has long served as Legal Cannabis Enemy No. 1 within the federal government, and this move potentially clears the way for national legalization.
And it served as a big catalyst for pot stocks.
Of course, national legalization is still a half-decade or more away, Sessions or not. At least that's what former Speaker of the House John Boehner says.
At the state level… well, there's another story.
On Tuesday (Nov. 6), Election Day, voters in three states passed legalization ballot initiatives.
In Missouri and Utah, voters made their states the 31st and 32nd to legalize medical marijuana.
And in Michigan, voters decided – with a 55% majority – to legalize adult-use recreational marijuana.
As the state with the second-biggest medical marijuana industry, this new marijuana reform cracks open a huge industry for Michigan. If we use Colorado's industry as a reference point, we're looking at $600 million in sales in the first year.
THREE STOCKS: Any one of these cannabis companies could potentially deliver a 1,000% windfall. Click here to learn more…
But here's the thing: Colorado's population is half the size of Michigan's. With 10 million residents, Michigan is the 10th most populated state in the nation.
Which means Michigan's market is potentially twice as big as Colorado's. There's a good chance it could easily break the $1 billion mark in sales… and that's just in the first year.
Already, Michigan's medical cannabis industry is second to only California's. In May 2018, Michigan had about 269,553 medical cannabis patients – and that was six months ago. They raked in $633 million in sales in 2017, outselling the other 30 medical-only cannabis states.
North Dakota, on the other hand, disappointed on Election Day by rejecting its proposed marijuana reform, which would have legalized recreational marijuana for adult use.
The thing is, the state's tiny population is conservative, and its ballot initiative was needlessly permissive. Under the measure, there would be no limits on the amount of cannabis people could possess or grow, and had no rules whatsoever outlining legal sales.
Expect to see another – more sensible – bill in North Dakota in the future.
The big thing we're celebrating with this election is the end of the liberal states' monopoly on cannabis legalization. Typically red states like Missouri and Utah are embracing legalization, and we can expect others to follow their lead.
A nationwide push seems practically inevitable at this point.
When laws pass… stocks soar.
And federal legalization would be an awfully big law.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.